Study guide
11.2 Hemostasis and Coagulation
Scientist in Blood Banking, BB ASCP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility Routes and Application 1.3 CMP, Credential Citation, and BB vs SBB
2 Donors and Collection
2.1 Donor Qualification 2.2 Collection Methods and Adverse Reactions 2.3 Special Donations
3 Processing, Storage, and Component QC
3.1 Processing: FDA/AABB Requirements, Testing, and Labeling 3.2 Anticoagulants, Additives, and Storage Temperatures 3.3 Transportation, Stored-Product Properties, and Expiration 3.4 Blood Component Quality Control
4 Blood Components
4.1 Red Blood Cells, Whole Blood, Washed, Frozen, and Rejuvenated 4.2 Platelets, Plasma, and Cryoprecipitated AHF 4.3 Granulocytes, Leukoreduced, and Irradiated Components 4.4 Apheresis Products, Fractionation, and Hematopoietic Progenitors
5 Blood Group Genetics and Transfusion Role
5.1 Basic and Molecular Genetics 5.2 Inheritance of Blood Groups 5.3 Immunogenicity and Antigen Prevalence
6 ABO and Lewis Systems
6.1 ABO Biochemistry and Antigens 6.2 ABO Antibodies, Discrepancies, and Subgroups 6.3 Lewis System
7 Rh System
7.1 Rh Genetics and Antigens 7.2 Weak D, Partial D, and Rh Antibodies 7.3 Rh Phenotyping and Clinical Significance
8 Kell, Duffy, Kidd, and MNS
8.1 Kell System 8.2 Duffy System 8.3 Kidd System 8.4 MNS System
9 Additional Systems and Antigens
9.1 P1PK, Globoside, and Ii Systems 9.2 Lutheran and Other Blood Group Systems 9.3 High- and Low-Prevalence Antigens 9.4 HLA, Platelet-Specific, and Granulocyte-Specific Antigens
10 Immunology Foundations
10.1 Immune Response, B and T Cells, Macrophages 10.2 Immunoglobulins: Classes, Structure, and Properties 10.3 Antigen-Antibody Interactions and Testing 10.4 Complement Pathways and Biologic Properties
11 Physiology, Hemostasis, Cytopenias, and Transplantation
11.1 Physiology of Blood 11.2 Hemostasis and Coagulation 11.3 Immune and Nonimmune Cytopenias 11.4 Solid Organ and HPC Transplantation
12 Hemolytic Disease of the Fetus and Newborn
12.1 HDFN Pathophysiology 12.2 HDFN Detection 12.3 HDFN Treatment and Prevention
13 Routine Serologic Testing
13.1 Blood Grouping Tests 13.2 Antibody Detection 13.3 Compatibility Testing and Crossmatch 13.4 Direct Antiglobulin Testing
14 Antibody Identification
14.1 Antibody Identification and Rule-Out 14.2 Clinical Significance, Dosage, and Multiple Antibodies 14.3 Panel Problem-Solving and Common Traps
15 Reagents and Special Techniques
15.1 Antiglobulin Sera, Grouping Sera, and Reagent Red Cells 15.2 Enzymes, Enhancement Media, and Lectins 15.3 Adsorption, Elution, Titration, and Cell Separations 15.4 Molecular, Solid-Phase, Column, ELISA, and Related Methods
16 Serologic QA and Special Reagents
16.1 Blood Sample Quality Assurance 16.2 Reagent and Procedure Quality Assurance 16.3 Thiol Reagents, Neutralization, Chloroquine, EGA, and Immunofluorescence
17 Indications and Component Therapy
17.1 Indications for Transfusion 17.2 Red Cell and Whole Blood Therapy 17.3 Platelet, Plasma, and Cryoprecipitate Therapy 17.4 Special Component Therapy
18 Adverse Effects of Transfusion
18.1 Immunologic Transfusion Reactions 18.2 Nonimmunologic Transfusion Reactions 18.3 Transfusion-Transmitted Diseases
19 Apheresis, Administration, and Patient Blood Management
19.1 Apheresis and Extracorporeal Circulation 19.2 Blood Administration 19.3 Patient Blood Management
20 Laboratory Operations
20.1 Quality Assessment and Troubleshooting 20.2 Quality Control, Proficiency Testing, and Regulation 20.3 Laboratory Safety 20.4 Laboratory Mathematics and Instrumentation
11.2 Hemostasis and Coagulation
Key Takeaways Explain This Topic AI
Primary hemostasis is platelet adhesion/aggregation plus vWF (GPIb–vWF, GPIIb/IIIa–fibrinogen). Secondary hemostasis is the coagulation cascade that lays down fibrin, then Factor XIII cross-links it.
Vitamin K–dependent factors are II, VII, IX, and X (plus proteins C and S). Labile factors are V and VIII — the reason FFP is frozen within 8 hours and why thawed plasma is a poor dedicated Factor VIII dose.
PT/INR watches the extrinsic path, especially Factor VII. aPTT watches the intrinsic path (VIII, IX, XI, XII). Thrombin time tests fibrinogen. A mixing study that corrects is a deficiency; one that does not is an inhibitor.
Thrombocytopenia is a count problem; aspirin, uremia, Glanzmann thrombasthenia, and Bernard–Soulier are function problems. Aspirin permanently impairs that platelet for its 8–10 day life.
Issue platelets for count or function, plasma for multiple-factor deficiency, cryoprecipitate for fibrinogen/FXIII (and selected vWF), and a specific concentrate whenever one is available.
Last updated: August 2026
11.2 Hemostasis and Coagulation
Quick Answer: Primary hemostasis is platelets plus vWF . Secondary hemostasis is the coagulation cascade. Vitamin K–dependent factors are II, VII, IX, X (and proteins C and S). Labile factors are V and VIII — that is why FFP is frozen within 8 hours . PT/INR watches the extrinsic path ( VII ); aPTT watches the intrinsic path ( VIII, IX, XI, XII ). Issue platelets for count or function, plasma for multiple-factor deficiency, cryo for fibrinogen/FXIII (and selected vWF), and a concentrate when a single factor is missing.
This is outline III.B.2 . Chapter 4.2 told you what is in the bag and how long it lasts. This section is why that bag exists: name the lesion, name the assay, pick the product.
Primary versus secondary hemostasis
Vascular injury starts primary hemostasis . Exposed collagen and endothelial vWF recruit platelets. Platelets adhere through GPIb-IX-V binding vWF , then aggregate through GPIIb/IIIa binding fibrinogen . The plug stops capillary and mucosal bleeding — petechiae, epistaxis, immediate surgical oozing. Defects live here: thrombocytopenia, aspirin or uremic dysfunction, Glanzmann thrombasthenia (no GPIIb/IIIa), Bernard–Soulier (no GPIb), and von Willebrand disease.
Secondary hemostasis is fibrin that welds that plug. Tissue factor plus Factor VII starts the extrinsic path. Contact factors XII, XI, IX, and VIII are the intrinsic path. Both activate X , then V , II (prothrombin → thrombin) , and I (fibrinogen → fibrin) . Factor XIII covalently cross-links fibrin. Defects look like deep hematomas, hemarthroses, and delayed re-bleeding — hemophilia, vitamin K deficiency/warfarin, liver failure, DIC, FXIII deficiency.
The blood bank is not the coagulation bench, but BB items expect you to map the bleeding pattern to the component.
Factors you must be able to name
Vitamin K–dependent: II, VII, IX, X , plus regulatory protein C and protein S . Warfarin and nutritional vitamin K deficiency lower this set together. Factor VII has the shortest half-life (about 4–6 hours ), so PT/INR prolongs first . Four-factor PCC (II, VII, IX, X) plus vitamin K is preferred for urgent warfarin reversal when available; FFP is the historical volume-heavy substitute.
Labile factors: V and VIII. They decay in liquid plasma at 1–6 °C. That is the physiologic reason FFP must be frozen within 8 hours and why PF24 has modestly lower VIII (Chapter 4.2). After thaw, VIII and V continue to fall, so thawed plasma through day 5 is not a dedicated Factor VIII dose . Hemophilia A is VIII ; treat it with a concentrate , not generic FFP, when a concentrate exists. There is still no standalone U.S. Factor V concentrate — multiple-factor or isolated V deficiency that needs replacement is a plasma problem.
Fibrinogen (Factor I) is the substrate thrombin acts on. Critical hypofibrinogenemia in a bleeding adult is commonly treated at < 100–150 mg/dL (higher obstetric targets appear on some protocols). That is cryoprecipitate or fibrinogen concentrate , not a four-unit FFP gesture. Each conventional cryo unit is manufactured toward ≥ 150 mg fibrinogen .
Factor XIII cross-links fibrin. Deficiency is rare, PT and aPTT are normal , and bleeding is delayed. Replacement is FXIII concentrate , or cryo if concentrate is not available.
vWF is in plasma and is concentrated in cryo. Mild type 1 disease may respond to DDAVP . Significant type 2 or type 3 needs a vWF-containing concentrate . Cryo is a fallback, not first-line when a licensed concentrate is on the shelf.
- Factor / protein Path / exam note Typical product
- I (fibrinogen) Common-path substrate Cryo or fibrinogen concentrate
- II, VII, IX, X Vitamin K–dependent PCC (warfarin); plasma if no PCC
- V Labile; no U.S. concentrate Plasma
- VIII Labile; intrinsic; hemophilia A FVIII concentrate, not FFP first
- IX Vitamin K; hemophilia B FIX concentrate
- XI Intrinsic; can bleed Plasma if replacement needed
- XII Prolongs aPTT; does not cause bleeding No product
- XIII Cross-link; PT/aPTT normal FXIII concentrate or cryo
- vWF Primary hemostasis vWF concentrate; cryo if no concentrate
- PT, aPTT, thrombin time, mixing studies
PT/INR uses tissue-factor (thromboplastin) reagent. It is prolonged by VII and by common-path X, V, II, and fibrinogen , and by warfarin. An isolated long PT → think Factor VII first.
aPTT uses a contact activator. It is prolonged by XII, XI, IX, VIII , common-path factors, heparin, and many lupus anticoagulants. Isolated long aPTT plus bleeding → VIII, IX, or XI . Isolated long aPTT without bleeding → XII, prekallikrein/HMWK, or lupus anticoagulant . Do not issue plasma to “correct” a lupus anticoagulant that is not a bleeding diathesis.
Thrombin time (TT) adds thrombin to plasma. It is prolonged by low or dysfibrinogenemia, heparin, and fibrin(ogen) degradation products . Reptilase time is heparin-insensitive and splits heparin from a fibrinogen problem.
Mixing study: 1:1 patient plasma + normal plasma. Correction means factor deficiency . Failure to correct means inhibitor (specific factor inhibitor or lupus anticoagulant). Some Factor VIII inhibitors are time-dependent: the mix corrects immediately and prolongs after incubation. Incubate when the story is hemophilia with new poor recovery.
BB relevance: a panagglutinin on a panel is not a mixing study. If the clinical team wants “factors,” ask which assay is abnormal and whether the mix corrected before issuing four FFP.
Platelet disorders the outline expects
Thrombocytopenia is a count problem (ITP, marrow failure, consumption, dilution). Dysfunction is a function problem at a normal or near-normal count.
Aspirin / many NSAIDs — COX-1 block, less thromboxane A2. Aspirin is irreversible for that platelet’s 8–10 day life. Platelet transfusion can supply unaffected platelets if bleeding is life-threatening; it is not an antidote you give for every aspirin tablet.
Uremia — retained toxins impair adhesion and aggregation. First moves are dialysis and DDAVP , not reflexive platelets. Transfuse platelets if the patient is still bleeding through those measures.
Glanzmann thrombasthenia — absent GPIIb/IIIa . Aggregation fails with all usual agonists except ristocetin. Patients can make anti-GPIIb/IIIa and become platelet-refractory.
Bernard–Soulier — absent GPIb , giant platelets, no ristocetin aggregation. Same “function, not count” transfusion logic.
Do not diagnose these from a type-and-screen. Do recognize the name and pick platelet support plus hematology , not FFP.
Component choice
Platelets — count below the institutional trigger (often 10 × 10^9/L prophylactically in a stable inpatient; higher for bleeding or an invasive procedure) or known dysfunction with bleeding.
Plasma (FFP/PF24) — multiple-factor deficiency: bleeding liver failure, bleeding DIC, massive transfusion, TTP as the plasma-exchange replacement fluid (ADAMTS13), or emergency warfarin reversal when PCC is not available. A typical dose is about 10–20 mL/kg , not “two units for every adult.”
Cryoprecipitate — fibrinogen, FXIII, and selected vWF/VIII when concentrates are not available. Cryo is not a warfarin-reversal product: it is the wrong factor set and the wrong volume of II/VII/IX/X.
Concentrates preferred when available — PCC, fibrinogen concentrate, FVIII, FIX, FXIII, vWF, and labeled recombinant VIIa settings. Specific, virally safer, smaller volume.
Worked scenario. A bleeding patient on warfarin has INR 4.2, fibrinogen 280 mg/dL, and platelets 180 × 10^9/L. The missing set is vitamin K–dependent factors. PCC plus vitamin K is first-line. FFP is the substitute if PCC is not in house. Cryo will not fix the INR. Platelets will not fix the INR.
Exam traps. Labile = V and VIII , not the vitamin K set. PT is VII/extrinsic ; aPTT is VIII/IX/XI/XII . A mix that does not correct is an inhibitor . Cryo is fibrinogen/FXIII/vWF, not PCC. Aspirin is a function problem for the life of that platelet. Factor XII does not get a product.